Swedish pharmaceutical company Camurus (NASDAQ STO:CAMX) said on Monday that it has received the US Food and Drug Administration's (FDA) Prescription Drug User Fee Act (PDUFA) goal date of 26 December 2018 for its investigational CAM2038 for the treatment of opioid use disorder (OUD).
Upon approval, CAM2038 would be the first long-acting treatment for OUD available in both weekly and monthly formulations for use through all stages of a patient's treatment journey, according to the company.
Based on the company's proprietary FluidCrystal injection depot technology, CAM2038 is designed to enable dose matching to existing sublingual buprenorphine formulations and for treatment initiation without the need to first stabilize patients on daily transmucosal buprenorphine products.
The US FDA's Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee had earlier recommended the approval of CAM2038 based on a review of results from the company's seven Phase 1-3 clinical trials, five of which were in patients with opioid dependence.
Additionally, CAM2038 is under regulatory review for marketing authorisation in the EU and Australia, stated the company.
Opioid use disorder and opioid-related overdose deaths are escalating global health problems, contributing to significant mental, physical and social adverse consequences that include transmission of infectious diseases, unintentional overdose, criminal activity and incarceration.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial